2022 Speakers

Government Speakers

David Derusha

Assistant U.S. Attorney
U.S. Attorney's Office for the District of Massachusetts

Analyzing DOJ Enforcement Priorities in Light of Recent OIG Guidance and Initiatives for the Life Sciences Industry

July 20, 2022 • 11:15 am

Allan Medina

Acting Senior Deputy Chief
U.S. Department of Justice, Criminal Division, Fraud Section

Analyzing DOJ Enforcement Priorities in Light of Recent OIG Guidance and Initiatives for the Life Sciences Industry

July 20, 2022 • 11:15 am

Amanda Page Masselam Strachan

Assistant United States Attorney
Chief, Health Care Fraud Unit
U.S. Attorney's Office, District of Massachusetts

Analyzing DOJ Enforcement Priorities in Light of Recent OIG Guidance and Initiatives for the Life Sciences Industry

July 20, 2022 • 11:15 am

Julie Ritchie Wagner

Head of Global Ethics, Compliance & Enforcement Legal Policy
Pharmaceutical Research and Manufacturers of America (PhRMA)

What the Adoption of OIG Speaker Program Guidance into the PhRMA Code Will Mean for the Industry

July 20, 2022 • 9:15 am

Co-Chairs

Heather Hurst

Global Director, Global Ethics & Compliance Officer
Cook Medical

Establishing Best Practices for Interacting with Health Care Professionals to Ensure Ethical Business Conduct and Fraud & Abuse Risk Mitigation

July 20, 2022 • 4:00 pm

Richard S. Liner

Senior Assistant General Counsel
Bayer

Navigating the Latest Fraud & Abuse Risks Associated with Payer Relationships, Value-Based Arrangements and Market Access Agreements

July 20, 2022 • 1:45 pm

Speakers

Tracy Palmer Berns

SVP, Chief Compliance & Quality Assurance Officer
Ionis Pharmaceuticals, Inc.

Compliance Executive Perspectives on the Latest OIG Pronouncements and the Evolving PhRMA Code: Thoughts on Speaker Programs, Kickback Risks and Forecasts for Future Fraud and Abuse Guidance

July 20, 2022 • 10:00 am

Jennifer Bragg

Partner, Life Sciences and Health Care; Litigation
Skadden, Arps, Slate, Meagher & Flom LLP

Evaluating the Potential Fraud and Abuse Risks Associated with Personalized Medicine

July 20, 2022 • 3:00 pm

Arbella Cherkis

Ethics & Compliance Director, US Specialty
GSK

Compliance Executive Perspectives on the Latest OIG Pronouncements and the Evolving PhRMA Code: Thoughts on Speaker Programs, Kickback Risks and Forecasts for Future Fraud and Abuse Guidance

July 20, 2022 • 10:00 am

Katherine DeKam

Chief Compliance Officer
Acumed

Compliance Executive Perspectives on the Latest OIG Pronouncements and the Evolving PhRMA Code: Thoughts on Speaker Programs, Kickback Risks and Forecasts for Future Fraud and Abuse Guidance

July 20, 2022 • 10:00 am

Heather Hurst

Global Director, Global Ethics & Compliance Officer
Cook Medical

Establishing Best Practices for Interacting with Health Care Professionals to Ensure Ethical Business Conduct and Fraud & Abuse Risk Mitigation

July 20, 2022 • 4:00 pm

Vladimir Jeune

Associate General Counsel – Market Access and Operations
EMD Serono, Inc.

Navigating the Latest Fraud & Abuse Risks Associated with Payer Relationships, Value-Based Arrangements and Market Access Agreements

July 20, 2022 • 1:45 pm

Anna Laakmann

Senior Counsel - Global Commercial Operations
Amgen

Evaluating the Potential Fraud and Abuse Risks Associated with Personalized Medicine

July 20, 2022 • 3:00 pm

Richard S. Liner

Senior Assistant General Counsel
Bayer

Navigating the Latest Fraud & Abuse Risks Associated with Payer Relationships, Value-Based Arrangements and Market Access Agreements

July 20, 2022 • 1:45 pm

Nathaniel (Nate) Mendell

Partner
Morrison & Foerster LLP

Establishing Best Practices for Interacting with Health Care Professionals to Ensure Ethical Business Conduct and Fraud & Abuse Risk Mitigation

July 20, 2022 • 4:00 pm

Dan Moynihan

Chief Compliance Officer
Spero Therapeutics

John D. W. Partridge

Partner
Gibson Dunn & Crutcher LLP

Evaluating the Potential Fraud and Abuse Risks Associated with Personalized Medicine

July 20, 2022 • 3:00 pm

Andrew Ruskin

Partner
K&L Gates LLP

Navigating the Latest Fraud & Abuse Risks Associated with Payer Relationships, Value-Based Arrangements and Market Access Agreements

July 20, 2022 • 1:45 pm

Matt Wetzel

Partner
Goodwin Procter LLP

Establishing Best Practices for Interacting with Health Care Professionals to Ensure Ethical Business Conduct and Fraud & Abuse Risk Mitigation

July 20, 2022 • 4:00 pm

Adam Yoffie

Senior Corporate Counsel, Litigation & Government Investigations
Bristol Myers Squibb

Establishing Best Practices for Interacting with Health Care Professionals to Ensure Ethical Business Conduct and Fraud & Abuse Risk Mitigation

July 20, 2022 • 4:00 pm

Jane H. Yoon

Jane H. Yoon

Partner
Paul Hastings LLP

Analyzing DOJ Enforcement Priorities in Light of Recent OIG Guidance and Initiatives for the Life Sciences Industry

July 20, 2022 • 11:15 am